Analyst Takeaways: DaVita Earnings Highlight IKC Progress; Key Q1-Q2 Watchpoints (DVA)

DaVita (DVA) outperformed expectations in Q4 2025, with revenue and non-GAAP profit ahead of Street forecasts. Revenue per treatment growth and disciplined execution in Integrated Kidney Care (IKC) drove performance, despite a year-over-year operating margin contraction due to higher health benefit costs. CEO Javier Rodriguez noted improved patient outcomes, including better treatment adherence and lower hospitalizations. Key watchpoints include: flu vaccination rate restoration and adoption of new clinical protocols; IKC profit growth as the segment matures; the impact of the Elara Caring partnership on reducing missed treatments and hospitalizations; and policy changes and reimbursement trends. DVA closed at $138.80, up from $111.19 before the earnings, reflecting positive market reaction.